SGLT-2i is beneficial for weight loss, increases insulin sensitivity, lower blood pressure, has cardiovascular and cerebrovascular protective effects, and has a low risk of hypoglycemia (35–37); in addition, SGLT-2i can induce the conversion of glucosuria to a state of systemic energy deficit and attenuate cellular senescence as a caloric restriction mimetic (37); thus, it is suitable for MOD and MARD populations who are older, overweight, and at high risk of hypertension and CVD. Here, INS is linked to Hypoglycemia.